Please login to the form below

Not currently logged in
Email:
Password:

Catalent appoints two board members

Jack Stahl and Rolf Classon to advise drug development, delivery and supply company
catalent-rolf-classon

Catalent has named two experienced healthcare figures to its board of directors.

Jack Stahl, former CEO of cosmetics firms Revlon, and Rolf Classon, former chairman at Bayer Healthcare, will use to their experience to advise Catalent, a leading player in providing drug development, delivery and supply services to pharma companies.

Stahl headed Revlon from 2002 to 2006 following a stint as chief operating officer at the Coca-Cola Company. He also serves on the Boards of Coty, Delhaize Group, and the US board of advisers of CVC Capital.

Classon served as chairman at Bayer Healthcare from 2002 until 2004 as part of a long career at Bayer that began in 1991. His roles at the German company included a seven-year spell as president of Bayer Diagnostics.

“We welcome both Jack and Rolf to our Board,” said John Chiminski, President and CEO, Catalent. “Both are senior healthcare executives, with a wealth of knowledge and experience within the sector.”

20th August 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics